BioWorld

Jan. 8, 2002

Chiron Buying Matrix For $61M, Adding Tezacitabine To Pipeline

Chiron Corp., its eyes firmly focused on the cancer therapeutic tezacitabine, is acquiring Matrix Pharmaceutical Inc. for $61 million in cash. Read More

Alexion Starts Phase III Study With Heart Drug Pexelizumab

Rodents Modeling Parkinson s Disease Generate Dopaminergic Neurons To Stem Losses In PD

Tripos Collaborates With Pfizer To Help Build Compound Library

Other News To Note

Structural GenomiX Partners With Millennium, Aventis For Discovery

Alteon Raising $18.6M To Fund Discovery, Development Work

Genencor, Seattle Genetics Align To Develop Cancer Therapeutics

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Medical illustration showing layers of a blood vessel

Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

BioWorld Science

More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...

Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

BioWorld Science

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...